TWI726897B - 與人類ｃｒｔｈ２特異性結合之抗體 - Google Patents

與人類ｃｒｔｈ２特異性結合之抗體 Download PDF

Info

Publication number
TWI726897B
TWI726897B TW105122490A TW105122490A TWI726897B TW I726897 B TWI726897 B TW I726897B TW 105122490 A TW105122490 A TW 105122490A TW 105122490 A TW105122490 A TW 105122490A TW I726897 B TWI726897 B TW I726897B
Authority
TW
Taiwan
Prior art keywords
antibody
amino acid
human
cells
crth2
Prior art date
Application number
TW105122490A
Other languages
English (en)
Chinese (zh)
Other versions
TW201704262A (zh
Inventor
亀山直哉
安藤宗稔
小川進也
岡田和樹
Original Assignee
日商協和麒麟股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商協和麒麟股份有限公司 filed Critical 日商協和麒麟股份有限公司
Publication of TW201704262A publication Critical patent/TW201704262A/zh
Application granted granted Critical
Publication of TWI726897B publication Critical patent/TWI726897B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
TW105122490A 2015-07-15 2016-07-15 與人類ｃｒｔｈ２特異性結合之抗體 TWI726897B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015141633 2015-07-15
JP2015-141633 2015-07-15

Publications (2)

Publication Number Publication Date
TW201704262A TW201704262A (zh) 2017-02-01
TWI726897B true TWI726897B (zh) 2021-05-11

Family

ID=57757419

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105122490A TWI726897B (zh) 2015-07-15 2016-07-15 與人類ｃｒｔｈ２特異性結合之抗體

Country Status (10)

Country Link
US (3) US9938349B2 (enExample)
EP (1) EP3323832A4 (enExample)
JP (2) JP6309050B2 (enExample)
KR (1) KR20180030030A (enExample)
CN (1) CN107849139B (enExample)
AU (1) AU2016293807B2 (enExample)
CA (1) CA2992262A1 (enExample)
HK (1) HK1255839A1 (enExample)
TW (1) TWI726897B (enExample)
WO (1) WO2017010567A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
ES3052981T3 (en) 2017-01-24 2026-01-16 Kyowa Kirin Co Ltd Therapeutic or prophylactic agent for treating radiation damage
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN107779500A (zh) * 2017-10-25 2018-03-09 上海药明生物技术有限公司 一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
KR102991359B1 (ko) * 2018-12-28 2026-07-16 쿄와 기린 가부시키가이샤 TfR에 결합하는 이중 특이적 항체
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0851030A1 (en) * 1996-06-05 1998-07-01 BML Inc. PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO
WO2014144865A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Anti-crth2 antibodies and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093092A2 (en) * 2004-03-26 2005-10-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0851030A1 (en) * 1996-06-05 1998-07-01 BML Inc. PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO
WO2014144865A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Anti-crth2 antibodies and methods of use

Also Published As

Publication number Publication date
CN107849139B (zh) 2022-05-03
US20180222994A1 (en) 2018-08-09
US20180371100A1 (en) 2018-12-27
CN107849139A (zh) 2018-03-27
AU2016293807A1 (en) 2018-02-08
US20170121415A1 (en) 2017-05-04
HK1255839A1 (en) 2019-08-30
JP6309050B2 (ja) 2018-04-11
KR20180030030A (ko) 2018-03-21
US9938349B2 (en) 2018-04-10
TW201704262A (zh) 2017-02-01
EP3323832A1 (en) 2018-05-23
CA2992262A1 (en) 2017-01-19
AU2016293807B2 (en) 2022-03-17
JP2017038592A (ja) 2017-02-23
EP3323832A4 (en) 2018-12-26
JP2018138546A (ja) 2018-09-06
US10100120B2 (en) 2018-10-16
WO2017010567A1 (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
TWI501777B (zh) 人類抗ｃｄ２７單株抗體
JP6224619B2 (ja) 抗ｆｏｌｒ１抗体
JP6309050B2 (ja) ヒトｃｒｔｈ２に特異的に結合する抗体
WO2011155579A1 (ja) 抗Ｔｒｏｐ－２抗体
EP3970743A1 (en) Bispecific antibody binding to cd40 and fap
CN101978054A (zh) 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
JP7506607B2 (ja) ＴｆＲに結合するバイスペシフィック抗体
US11485779B2 (en) Anti-BMP10 monoclonal antibody or fragment thereof
AU2018302647B2 (en) Anti-human CCR1 monoclonal antibody
TWI707868B (zh) 抗人類Ｇａｓ６單株抗體
JP7502281B2 (ja) Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees